

# WINNING THE WAR AGAINST CANCER

MONDAY JUNE 25, 2018

8:30



### Welcome and opening remarks

The 10<sup>th</sup> Anniversary of the WIN Consortium: lessons and perspectives

*Richard L. Schilsky, Chairman WIN Consortium, American Society of Clinical Oncology (ASCO®), USA*

8:50



### Opening Lecture: WINTHER trial

*Razelle Kurzrock, University of California San Diego (UCSD), USA*

### PRESIDENTIAL SESSION 1: THE CHALLENGES OF BUILDING REAL COOPERATION TO IMPLEMENT PRECISION ONCOLOGY PROGRAMS: A LONG AND WINDING ROAD

**Chairs:** *Richard L. Schilsky, ASCO, USA, Chairman of WIN Consortium; Jean-Charles Soria, MedImmune, USA*

9:20



### Keynote Lecture: The TAPUR family of clinical trials: building a global data sharing platform in Precision Oncology

*Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA*

9:50



### Making Cancer History all together

*Stephen M. Hahn, The University of Texas MD Anderson Cancer Center (UT-MDACC), USA*

10:20



### U.S. National Cancer Institute perspective on Precision Oncology

*James H. Doroshow, National Cancer Institute (NCI), USA*

10:50 Coffee break, networking

11:15



### Beyond standard of care: the next steps of Precision Oncology - an ESMO perspective

*Josep Tabernero, Vall d'Hebron Institute of Oncology (VHIO), Spain. President European Society for Medical Oncology (ESMO), Switzerland*

11:45



### The future of the EU Framework programmes for research and innovation

*Cornelius Schmaltz, Head of Unit Health Research Strategy, Directorate General for Research and Innovation at the European Commission in Brussels, Belgium*

12:15

### Open Forum and Debate with the audience: The key issues of worldwide cooperation

- Technology and conceptual breakthroughs
- Industry or academic sponsored research
- Funding of clinical trials
- Publication policies

#### Moderators:

*Lisa Hutchinson, Foundation for World Health (FWH), UK, WIN Consortium  
Jean-Charles Soria, MedImmune, USA*

#### Panel:

*James H. Doroshow, NCI, USA  
Stephen M. Hahn, UT-MDACC, USA  
Richard L. Schilsky, ASCO, USA  
Cornelius Schmaltz, European Commission, Belgium  
Josep Tabernero, VHIO, Spain, ESMO*

13:15 Lunch break, poster viewing and networking

### SESSION 2: THE NEXT FRONTIER OF THERAPEUTICS IN NEWLY DIAGNOSED PATIENTS: STANDARD OF CARE OR MODERN BIOMARKER DRIVEN PRECISION ONCOLOGY?

**Chairs:** *Razelle Kurzrock, UCSD, USA; Josep Tabernero, VHIO, Spain, ESMO*

14:15



### The systems biology approach to Precision Oncology: ready to defeat cancer

*Leroy Hood, Institute for Systems Biology (ISB), USA*

14:45



### A new world of early diagnosis to defeat Non-Small Cell Lung Carcinoma (NSCLC); The WIN Consortium BOOSTER trial for identification and validation of new blood biomarkers for NSCLC

*Amir Onn, Sheba Medical Center, Israel*

15:00



### Lessons from long-term survey of Stage I NSCLC

*Harvey I. Pass, New York University (NYU), Langone Health, USA*

15:15 Coffee break, networking

## ORGANIZING COMMITTEE

### CHAIRS:

*John Mendelsohn (USA)  
Razelle Kurzrock (USA)*

### MEMBERS:

*Lisa Hutchinson (UK)  
Brian Leyland-Jones (USA)  
Amir Onn (Israel)  
Richard L. Schilsky (USA)  
Chang-Sik Yu (South Korea)  
Vladimir Lazar (France)  
Catherine Bresson (France)*

## MONDAY JUNE 25, 2018 - CONTINUED

15:40



**Keynote Lecture:** Patients' expectations and hopes  
*Ellen V. Sigal, Friends of Cancer Research, USA*

16:10



Newly diagnosed breast cancer at the frontier of Precision Oncology  
*Laura Esserman, University of California San Francisco (UCSF), USA*

17:40 **Open forum and debate with the audience: Next frontiers of therapeutics**

**Moderators:**

*Razelle Kurzrock, UCSD, USA*  
*Josep Taberbero, VHIO, Spain, ESMO*

**Panel:**

*Laura Esserman, UCSF, USA*  
*Leroy Hood, Institute for Systems Biology (ISB), USA*  
*Amir Onn, Sheba Medical Center, Israel*  
*Harvey I. Pass, NYU Langone Health, USA*  
*Ellen V. Sigal, Friends of Cancer Research, USA*

17:40

WELCOME RECEPTION, NETWORKING AND POSTER VIEWING running at the same time as

18:30

**MEET THE PROFESSOR** sessions to choose from:

- Meeting 1:** *Razelle Kurzrock, University of California San Diego (UCSD), USA*  
*Josep Taberbero, Vall d'Hebron (VHIO), Spain; President (ESMO), Switzerland*
- Meeting 2:** *James H. Doroshow, National Cancer Institute (NCI), USA*  
*Richard L. Schilsky, American Society of Clinical Oncology (ASCO), USA*
- Meeting 3:** *Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium*  
*Ellen V. Sigal, Friends of Cancer Research, USA*
- Meeting 4:** *Carl H. June, Perelman School of Medicine, USA*  
*Laura Esserman, University of California San Francisco, USA*
- Meeting 5:** *Jean-Charles Soria, MedImmune, USA*  
*Apostolia-Maria Tsimberidou, University of Texas, MD Anderson Cancer Center (UT-MDACC), USA*

20:00

Gala dinner (departure 19:30)

## TUESDAY JUNE 26, 2018

SESSION 3: **DISRUPTIVE CONCEPTS AND CLINICAL TRIALS SHIFTING THE PARADIGM OF PRECISION ONCOLOGY**

**Chairs:** *Carl H. June, Perelman School of Medicine, USA; Richard L. Schilsky, ASCO, USA*

8:30



**Keynote Lecture:** Combinations of monoclonal antibodies overcome resistance to drugs  
*Yosef Yarden, Weizmann Institute of Science, Israel*

8:55



The first targeted agents tri-therapy combination trial in first therapeutic line of metastatic NSCLC: the WIN Consortium SPRING\_01 trial  
*Razelle Kurzrock, University of California San Diego (UCSD), USA*

9:20



The challenges of combining targeted therapies in biomarker driven Precision Oncology – a Pharma perspective  
*Jean-François Martini, Pfizer Inc., USA*

9:45



MyPathway study: a novel precision oncology multiple basket trial  
*Mary Beattie, Genentech, USA*

10:10

Coffee break, networking

## TUESDAY JUNE 26, 2018 - CONTINUED

### SESSION 4: **NEW CONCEPTS AND THERAPEUTICS AVENUES IN PRECISION ONCOLOGY**

*Chairs: Alan Spatz, McGill Segal Cancer Center, Canada; Phillip Febbo, Illumina, USA*

10:40



**Keynote Lecture:** Precision CAR T-cells therapeutics  
*Carl H. June, Perelman School of Medicine, 2017 David A. Karnofsky Memorial Award ASCO, USA*

11:05



Immunotherapies turning cold into hot tumors  
*Jean-Charles Soria, MedImmune, USA*

11:30



Precision Oncology approaches for immunotherapy  
*Eric Rubin, Merck, USA*

11:55



Early development in oncology: Are the MTD and monotherapy efficacy still the best objectives?  
*Giorgio Massimini, Merck KGaA, Germany*

12:20

### **Open forum and debate with the audience: The future of drug development for Precision Oncology**

**Moderators:**

*Alan Spatz, McGill Segal Cancer Centre, Canada  
Phillip Febbo, Illumina, USA*

**Panel:**

*Carl H. June, Perelman School of Medicine, USA  
Jean-François Martini, Pfizer Inc., USA  
Giorgio Massimini, Merck KGaA, Germany  
Eric Rubin, Merck, USA  
Richard L. Schilsky, ASCO, USA*

13:00 Lunch break, poster viewing and networking

### SESSION 5: **CHALLENGES OF THE COMBINATION OF TARGETED THERAPIES**

*Chair: Gerald Batist, McGill Segal Cancer Center, Canada*

14:00



Implementing Precision Medicine in Oncology: The IMPACT Clinical Trials at MD Anderson  
*Apostolia-Maria Tsimberidou, University of Texas, MD Anderson Cancer Center (UT-MDACC), USA*

14:50



The Greatest hits of Precision Oncology  
*Bernadette Toner, GenomeWeb, USA*

15:15



Access of patients to Precision Oncology  
*Francesco De Lorenzo, European Cancer Patient Coalition (ECPC), Belgium*

15:40 Coffee break, networking

### **2 best posters presentations**

### SESSION 6: **CELEBRATION OF THE LIFE AND ACHIEVEMENTS OF PROFESSOR THOMAS TURSZ**

*Vladimir Lazar, WIN Consortium, France  
Josep Taberero, Vall d'Hebron Institute of Oncology (VHIO), Spain,  
President - European Society for Medical Oncology (ESMO), Switzerland*

